NYSE:AVNS - Avanos Medical Stock Price Target and Predictions

  • Consensus Rating: Hold
  • Consensus Price Target: $38.40
  • Forecasted Upside: -17.51 %
  • Number of Analysts: 5
  • Breakdown:
  • 1 Sell Ratings
  • 2 Hold Ratings
  • 2 Buy Ratings
  • 0 Strong Buy Ratings
$46.55
▲ +2.17 (4.89%)
1 month | 3 months | 12 months
Get New Avanos Medical Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for AVNS and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for AVNS

i We calculate consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). Our consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. Our consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
$38.40
▼ -17.51% Downside Potential
This price target is based on 5 analysts offering 12 month price targets for Avanos Medical in the last 3 months. The average price target is $38.40, with a high forecast of $55.00 and a low forecast of $30.00. The average price target represents a -17.51% upside from the last price of $46.55.
Hold
The current consensus among 5 contributing investment analysts is to hold stock in Avanos Medical. This Hold consensus rating has held steady for over two years.

Past Monthly Recommendations

Move your mouse over past months for details

  • 0 strong buy ratings
  • 1 buy ratings
  • 4 hold ratings
  • 1 sell ratings
9/12/2019
  • 0 strong buy ratings
  • 1 buy ratings
  • 4 hold ratings
  • 1 sell ratings
12/11/2019
  • 0 strong buy ratings
  • 0 buy ratings
  • 4 hold ratings
  • 1 sell ratings
3/10/2020
  • 0 strong buy ratings
  • 2 buy ratings
  • 4 hold ratings
  • 1 sell ratings
6/8/2020
  • 0 strong buy ratings
  • 2 buy ratings
  • 3 hold ratings
  • 1 sell ratings
9/6/2020
  • 0 strong buy ratings
  • 2 buy ratings
  • 2 hold ratings
  • 1 sell ratings
12/5/2020
  • 0 strong buy ratings
  • 2 buy ratings
  • 2 hold ratings
  • 1 sell ratings
2/3/2021
  • 0 strong buy ratings
  • 2 buy ratings
  • 2 hold ratings
  • 1 sell ratings
3/5/2021

Latest Recommendations

  • 0 strong buy ratings
  • 2 buy ratings
  • 2 hold ratings
  • 1 sell ratings

DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
1/8/2021KeyCorpBoost Price TargetOverweight$47.00 ➝ $55.00Low
i
12/15/2020Morgan StanleyBoost Price TargetUnderweight$36.00 ➝ $45.00Medium
i
11/4/2020Morgan StanleyBoost Price TargetUnderweight$31.00 ➝ $36.00Low
i
11/4/2020KeyCorpBoost Price TargetOverweight$43.00 ➝ $47.00Low
i
8/5/2020KeyCorpLower Price TargetOverweight$45.00 ➝ $43.00High
i
5/7/2020Morgan StanleyBoost Price TargetUnderweight$29.00 ➝ $31.00High
i
4/27/2020KeyCorpLower Price TargetOverweight$48.00 ➝ $45.00High
i
4/13/2020BarclaysUpgradeUnderweight ➝ Equal Weight$30.00Medium
i
4/1/2020Stifel NicolausLower Price TargetHold$35.00 ➝ $32.00High
i
3/27/2020Morgan StanleyLower Price TargetSell$32.00 ➝ $29.00Low
i
3/23/2020StephensLower Price TargetOverweight$40.00 ➝ $30.00High
i
2/27/2020BarclaysReiterated RatingSell$32.00Medium
i
1/28/2020BarclaysReiterated RatingSell$30.00Low
i
12/17/2019Morgan StanleyLower Price TargetUnderweight$36.00 ➝ $32.00High
i
11/6/2019Stifel NicolausDowngradeBuy ➝ Hold$45.00 ➝ $35.00Low
i
Rating by Rick Wise at Stifel Nicolaus
11/6/2019Raymond JamesDowngradeOutperform ➝ Market PerformHigh
i
Rating by Lawrence Keusch at Raymond James
8/21/2019JMP SecuritiesReiterated RatingHoldN/A
i
Rating by David Turkaly at JMP Securities
8/7/2019Stifel NicolausSet Price TargetBuy$45.00Low
i
Rating by Rick Wise at Stifel Nicolaus
8/7/2019Raymond JamesLower Price TargetOutperform$57.00 ➝ $48.00Medium
i
5/8/2019Morgan StanleySet Price TargetSell$47.00Low
i
Rating by Jonathan Demchick at Morgan Stanley
2/27/2019KeyCorpLower Price TargetOverweight ➝ Overweight$67.00 ➝ $65.00High
i
1/4/2019BarclaysDowngradeEqual Weight ➝ UnderweightHigh
i
12/18/2018KeyCorpLower Price TargetOverweight ➝ Overweight$68.00 ➝ $67.00Low
i
10/15/2018BarclaysInitiated CoverageEqual Weight ➝ Equal Weight$69.00High
i
10/11/2018Morgan StanleyBoost Price TargetUnderweight$60.00 ➝ $62.00Low
i
8/21/2018Raymond JamesUpgradeMarket Perform ➝ OutperformHigh
i
8/8/2018Morgan StanleyBoost Price TargetUnderweight ➝ Underweight$58.00 ➝ $60.00Medium
i
8/8/2018KeyCorpBoost Price TargetOverweight ➝ Overweight$66.00 ➝ $75.00High
i
(Data available from 3/5/2016 forward)
Avanos Medical logo
Avanos Medical, Inc. operates as a medical technology company that focuses on delivering medical device solutions to improve patients' quality of life in North America, Europe, the Middle East, Africa, the Asia Pacific, and Latin America. Its product portfolio includes digestive health products, including enteral feeding tubes and solutions; respiratory health products, such as closed airway suction systems and oral care kits; and acute pain products comprising surgical pain pumps, and cold and compression therapy systems, as well as interventional pain management solutions that include minimally invasive interventional pain therapies. The company sells its products under the MIC-KEY, CORPAK, NEOMED, BALLARD, MICROCUFF, ENDOCLEAR, ON-Q, AMBIT, GAME READY, and COOLIEF brand names. It markets its products directly to hospitals and other healthcare providers, and through third-party wholesale distributors. The company was formerly known as Halyard Health, Inc. and changed its name to Avanos Medical, Inc. in June 2018. Avanos Medical, Inc. was incorporated in 2014 and is headquartered in Alpharetta, Georgia.
Read More

Today's Range

Now: $46.55
$44.44
$46.72

50 Day Range

MA: $47.30
$44.38
$53.40

52 Week Range

Now: $46.55
$19.46
$53.61

Volume

232,276 shs

Average Volume

231,051 shs

Market Capitalization

$2.23 billion

P/E Ratio

160.52

Dividend Yield

N/A

Beta

1.12

Frequently Asked Questions

What sell-side analysts currently cover shares of Avanos Medical?

The following Wall Street analysts have issued stock ratings on Avanos Medical in the last year: Barclays PLC, KeyCorp, Morgan Stanley, Stephens, Stifel Nicolaus, TheStreet, and Zacks Investment Research.
View the latest analyst ratings for AVNS.

What is the current price target for Avanos Medical?

5 Wall Street analysts have set twelve-month price targets for Avanos Medical in the last year. Their average twelve-month price target is $38.40, suggesting a possible downside of 17.5%. KeyCorp has the highest price target set, predicting AVNS will reach $55.00 in the next twelve months. Barclays PLC has the lowest price target set, forecasting a price of $30.00 for Avanos Medical in the next year.
View the latest price targets for AVNS.

What is the current consensus analyst rating for Avanos Medical?

Avanos Medical currently has 1 sell rating, 2 hold ratings and 2 buy ratings from Wall Street analysts. The stock has a consensus analyst rating of "Hold." A "hold" rating indicates that analysts believe investors should keep any existing positions they have in AVNS, but not buy more shares or sell existing shares.
View the latest ratings for AVNS.

What other companies compete with Avanos Medical?

How do I contact Avanos Medical's investor relations team?

Avanos Medical's physical mailing address is 5405 Windward Parkway Suite 100 South, Alpharetta GA, 30004. The company's listed phone number is 844-428-2667 and its investor relations email address is [email protected] The official website for Avanos Medical is avanos.com.